Free Trial
OTCMKTS:HDII

Hypertension Diagnostics (HDII) Stock Price, News & Analysis

Hypertension Diagnostics logo

About Hypertension Diagnostics Stock (OTCMKTS:HDII)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
20,001 shs
Market Capitalization
$30,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada.

Receive HDII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hypertension Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

HDII Stock News Headlines

Market down? Do this now.
The Trump administration's new tariffs have already begun to shake the economy. The impact is real, and the clock is ticking. If you don't act now, your savings could be in serious jeopardy. At Colonial Metals, we're here to help you take control of your financial future. That's why we've created a FREE Wealth Protection Guide to show you how to protect your wealth during these uncertain times.
Hypertension Diagnostics Inc (HDII)
PASO Patient Access Solutions, Inc.
See More Headlines

HDII Stock Analysis - Frequently Asked Questions

Shares of HDII stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hypertension Diagnostics investors own include Actinium Pharmaceuticals (ATNM), Genocea Biosciences (GNCA), Victory Square Technologies (VSQTF), China Biologic Products (CBPO), BioNTech (BNTX), Bionano Genomics (BNGO) and Baidu (BIDU).

Company Calendar

Today
2/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
OTCMKTS:HDII
CUSIP
44914V104
Employees
2,017
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
170,869,000
Market Cap
$30,000.00
Optionable
Not Optionable
Beta
N/A
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (OTCMKTS:HDII) was last updated on 2/23/2025 by MarketBeat.com Staff
From Our Partners